The Next Wave in China’s Medtech: Noteworthy PFA Innovation

August 22, 2025

Pulse Field Ablation (PFA) has rapidly emerged as a foundational technology in cardiac electrophysiology, promising a new era of safer, more efficient, and more accessible cardiac ablation procedures. As global players like Medtronic and Boston Scientific lead this charge, a parallel revolution is unfolding in China, driven by a growing cohort of domestic innovators. Nearly one-third of the NMPA-approved innovative products in the first half of 2025 were PFA-related devices. For international Medtech stakeholders—understanding this dynamic landscape is no longer a niche interest; it is a strategic imperative.

1. Technical Innovation: Beyond Conventional PFA

Nowadays, Chinese Medtech firms are not simply replicating existing PFA technology; they are actively pursuing next-generation solutions. Rather than simply creating ‘me-too’ products, a growing number of Chinese innovators are focusing on differentiated technology that helps them stand out from the competition. Distinct energy and design pathways are worth to note among others.

• Energy Modulation: A notable development is the emergence of nanosecond PFA (ns-PFA) systems. Companies like Pulsecare Medical are developing platforms that use high-voltage nanosecond pulses. Clinical data from their trials, such as the SCENA-AF multicenter study, suggest this approach significantly reduces neuromuscular stimulation, potentially allowing procedures to be performed under conscious sedation rather than general anesthesia. This could enhance patient comfort and lower procedural costs. In addition, technologies such as gradient-field PFA, which are designed to achieve true non-thermal ablation, are being explored to further mitigate the risk of thermal injury. Another player worth to mention here is Shanghai Shangyang Medical Technology Co., Ltd. With the support of its strategic partner, Shanghai MicroPort EP Medtech Co., Ltd., Shangyang Medical’PFA products are compatible with the Columbus® 3D EP Navigation System from MicroPort EP, providing comprehensive solutions for atrial fibrillation treatment.
• Catheter Design: Chinese companies have focused on developing a range of catheter morphologies tailored for specific anatomies and procedural needs. This is a departure from a “one-size-fits-all” approach. Innovations include petal-shaped catheters designed for a larger ablation area and linear magnetic-electric catheters that offer millimeter-level precision.
• System Integration: The integration of PFA with advanced navigation and AI is a key area of focus. Companies are developing fully integrated 3D mapping and PFA systems, which can reduce overall procedure time and enhance procedural workflow. This trend points to a move beyond single-device innovation toward comprehensive procedural solutions. Sichuan Jinjiang Electronic Medical Device Technology Co., Ltd. (JJET), an innovative company focusing on cardiac electrophysiology, has created several Firsts in cardiac electrophysiology devices in China. Its main product, the LEAD-PFA Pulsed Field Ablation System, received NMPA approval in December 2023. This system is the first of its kind in China, combining a three-dimensional magnetoelectric positioning with PFA technology.

2. Clinical and Economic Impact

The innovation pipeline has translated into tangible clinical and economic outcomes within China.

• Procedural Efficiency: The clinical data highlights a significant reduction in procedure and active ablation times. This is a crucial factor for a market facing high patient volumes. Shorter procedures not only improve throughput but can also enhance patient outcomes by reducing anesthesia time and potential for complications.
• Safety Profile: Clinical trials conducted in China have reported a robust safety profile for domestic PFA systems, with a notably low incidence of major adverse events. While long-term follow-up data is still being gathered, initial results are promising and underscore the potential of these technologies to deliver safe and effective treatment.
• Accessibility: Perhaps the most disruptive element of China’s PFA market is the dramatic improvement in accessibility. Local devices, priced significantly lower due to China’s volume-based procurement (VBP) policies, are opening up PFA to a wider range of hospitals, including those at the county level. The disruptive price differential comparing to their imported counterparts—is a powerful market force that expands patient access and shifts the procedural landscape.

3. Strategic Considerations for Global Stakeholders

China’s innovations in PFA are significantly reshaping the global medical technology landscape for the treatment of atrial fibrillation (AFib). This is due to strong government backing, fast-paced research and development (R&D), and a large domestic market that is highly competitive and responsive to cost-effective solutions.

Chinese manufacturers are emerging as technology leaders, not just followers, particularly with their focus on advanced nanosecond PFA and new catheter designs. For anyone involved in strategic planning, from R&D to commercial portfolios, it’s crucial to follow these developments and engage with key Chinese stakeholders.